1
|
Remirez-Castellanos AL, Piña-Sanchez P, Mantilla-Morales A, Valenzuela-Gonzalez W, Candanedo González F. Human Papillomavirus-Related Recurrent Multiphenotypic Sinonasal Carcinoma With HPV Genotype 56 Detected by HPV Direct Flow CHIP. Cureus 2023; 15:e40413. [PMID: 37456483 PMCID: PMC10348072 DOI: 10.7759/cureus.40413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/13/2023] [Indexed: 07/18/2023] Open
Abstract
Human Papillomavirus-related multiphenotypic sinonasal carcinoma is a rare, and recently described neoplasm, defined by its association with high-risk Human Papillomavirus, which exclusively affects the sinonasal tract and simulates salivary gland tumors. Due to the infrequency of this neoplasm and the lack of knowledge of its pathological characteristics, it is susceptible to diagnostic error. We describe the clinical-radiological findings of a 54-year-old man with multiphenotypic sinonasal carcinoma related to Human Papillomavirus genotype 56. The diagnosis of multiphenotypic sinonasal carcinoma was suspected by light microscopy and was corroborated by immunohistochemistry and polymerase chain reaction (PCR) analysis. The patient was subsequently treated with 63.6 gray radiotherapies. He is currently alive after a follow-up of 20 months, with a recurrence of the disease. In conclusion, multiphenotypic sinonasal carcinoma is an unusual neoplasm, which is not well recognized and can be confused with adenoid cystic carcinoma. However, multiphenotypic sinonasal carcinoma should be included in the differential diagnosis as we encounter sinonasal tumors, which by histology present tubular, cribriform, and solid growth patterns, accompanied by dysplasia or carcinoma in situ in the superficial mucosa. In this case, it is necessary to perform immunohistochemistry for p16INK4A or PCR to confirm the presence of high-risk Human Papilloma Virus, which would confirm the diagnosis.
Collapse
Affiliation(s)
- Ana Lilia Remirez-Castellanos
- Radiology, Unidad Medico de Alta Especialidad (UMAE) Hospital de Oncologia, Centro Medico Nacional Siglo XXI. IMSS, Mexico, MEX
| | - Patricia Piña-Sanchez
- Medical Research Unit in Oncological Diseases, Unidad Medico de Alta Especialidad (UMAE) Hospital de Oncologia Centro Medico Nacional Siglo XXI. IMSS, Mexico, MEX
| | - Alejandra Mantilla-Morales
- Pathology, Unidad Medico de Alta Especialidad (UMAE) Hospital de Oncologia Centro Medico Nacional Siglo XXI. IMSS, Mexico City, MEX
| | | | - Fernando Candanedo González
- Pathology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, MEX
- Pathology, Unidad Medico de Alta Especialidad (UMAE) Hospital de Oncologia, Centro Medico Nacional Siglo XXI IMSS, Ciudad de México, MEX
| |
Collapse
|
2
|
Leal YA, Torres J, Gamboa R, Mantilla-Morales A, Piña-Sanchez P, Arrieta O, Bonifaz L, Meneses A, Duque C, Piñeros M. Cancer Incidence in Merida, Mexico 2015-2018: First Report from the Population-based Cancer Registry. Arch Med Res 2022; 53:859-866. [PMID: 36462950 DOI: 10.1016/j.arcmed.2022.11.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 11/23/2022] [Indexed: 12/03/2022]
Abstract
BACKGROUND Cancer registries are essential for monitoring cancer burden and patterns, and document changes in time for cancer control. Hereby, we present the first results of four years of the Merida population-based cancer registry in Mexico. METHODS The registry collects data on all new cancers diagnosed since 2015 using both active and passive methods including a total of 104 information sources. Definitions and coding follow international standards. Using CanReg5 software, age-standardized incidence rates (ASR/100,000 person years) were computed by direct method using the world standard population. RESULTS A total of 5684 new cancer cases were registered during 2015-2018, 2321 in males and 3363 in females corresponding to age-adjusted incidence rates (ASR per 100,000) of 128.5, and 153.1, respectively. Most frequent cancers among males were prostate cancer (ASR 29.8), lymphomas (ASR 10.9) and colorectal cancer (ASR 9.7) while among females it was breast cancer (ASR 49.3), cervical cancer (ASR 17.5) and corpus uteri (ASR 11.5). Childhood cancers (0-14 year) represented 2.9% of all cancers, with leukemias accounting for 52% of the new cases. Overall, 87.6% of new cases were microscopically verified. CONCLUSIONS The data reported provide information on the cancer profile in Merida. Prostate and breast cancer are the main incident cancers. Cervical cancers present high rates among women, while lymphomas and liver cancer data merit further exploration. Efforts to support the Merida cancer registry as well as other registries in Mexico need to be pursued in order to have locally recorded data to support cancer control measures.
Collapse
Affiliation(s)
- Yelda A Leal
- Centro Institucional de Capacitación y Registro de Cáncer, Unidad Médica de Alta Especialidad, Centro Médico Nacional, Ignacio García Téllez, Instituto Mexicano de Seguro Social, Mérida, Yucatán, México.
| | - Javier Torres
- Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Centro Médico Nacional Siglo XXI, Instituto Mexicano de Seguro Social, Ciudad de México, México
| | - Ricardo Gamboa
- Departamento de Oncología, Unidad de Investigación Médica en Enfermedades Oncológicas, Centro Médico Nacional, Ignacio García Téllez, Instituto Mexicano de Seguro Social, Mérida, Yucatán, México
| | - Alejandra Mantilla-Morales
- Laboratorio de Patología de la Unidad de Investigación Médica en Enfermedades Oncológicas, Oncología Centro Médico Nacional Siglo XXI, Instituto Mexicano de Seguro Social, Ciudad de México, México
| | - Patricia Piña-Sanchez
- Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Medico Nacional Siglo XXI, Ciudad de México, México
| | - Oscar Arrieta
- Coordinación del Registro Nacional de Cáncer del Instituto Nacional de Cancerología, Ciudad de México
| | - Laura Bonifaz
- Coordinación de Investigación en Salud, Centro Medico Nacional Siglo XXI, Instituto Mexicano de Seguro Social, Ciudad de México, México
| | - Abelardo Meneses
- Dirección General del Instituto Nacional de Cancerología, Ciudad de México, México
| | - Celida Duque
- Dirección de Prestaciones Médicas, Instituto Mexicano de Seguro Social, Ciudad de México, México
| | - Marion Piñeros
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, Francia
| |
Collapse
|
3
|
Cervantes-Díaz MT, Muñoz-Granados AJ, Olguín-Cruces VA, Ramírez-Torres N, Gutiérrez-Osorio V, Mantilla-Morales A, López-Muñoz E. BECN1 protein expression is associated with poor survival in triple negative locally advanced breast cancer. Eur Rev Med Pharmacol Sci 2022; 26:354-366. [PMID: 35113411 DOI: 10.26355/eurrev_202201_27860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
OBJECTIVE The role that Beclin 1 (BECN1) plays in the development and progression of cancer mediated by autophagy, as well as its differential expression in breast cancer cell lines and mammary tumor tissue according to the molecular subtype, has been demonstrated. The objective of this study was to evaluate the association of BECN1 cytoplasmic expression with clinical and pathologic response, recurrence, disease-free survival (DFS) and overall survival (OS) in patients with locally advanced breast cancer (LABC), according to immunophenotype. PATIENTS AND METHODS 64 patients with non-triple negative LABC and 20 patients with triple negative LABC who received preoperative chemotherapy were included in an observational, analytical and retrospective study to evaluate the cytoplasmic expression of BECN1 protein by immunohistochemistry in microarrays of breast cancer tissue obtained before treatment. Association between BECN1 and clinicopathological characteristics, clinical and pathologic response to preoperative chemotherapy and recurrence, were analyzed using Chi-square or Fisher's exact test. Postoperative DFS and OS were assessed by Kaplan-Meir curves, and the difference according to BECN1 expression was evaluated using the log-rank test. The bivariate analysis was performed using the Cox Proportional Hazards Model. A p-value of < 0.05 was considered statistically significant. RESULTS BECN1 staining revealed positive expression in 62.5% of patients with non-triple negative and 60.0% with triple negative LABC. No association was observed between BECN1 expression and clinical or pathological response or recurrence. An association of the BECN1 expression with lower OS in triple negative breast cancer was found (HR = 5.19; 95% CI 1.12-24.02; p = 0.035). CONCLUSIONS Results showed an association of the cytoplasmic expression of BECN1 with a lower OS, which could be a poor prognostic biomarker in triple negative LABC.
Collapse
Affiliation(s)
- M T Cervantes-Díaz
- Medical Research Unit in Reproductive Medicine, Unidad Médica de Alta Especialidad Hospital de Gineco Obstetricia No. 4 "Luis Castelazo Ayala", Instituto Mexicano del Seguro Social, Colonia Tizapan San Angel, Alcaldía Álvaro Obregón, Mexico City, Mexico.
| | | | | | | | | | | | | |
Collapse
|
4
|
Sandoval-Macias R, Ortiz-Sanchez ID, Remirez-Castellanos AL, Mora-Hernandez L, Cordova-Uscanga C, Mantilla-Morales A, Galindo-Garcia TA, Gamboa-Dominguez A, Candanedo-Gonzalez F. Retrospective analysis of the clinical presentation and imaging of eight primary benign mediastinal schwannomas. BMC Res Notes 2021; 14:278. [PMID: 34289875 PMCID: PMC8296632 DOI: 10.1186/s13104-021-05694-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Accepted: 07/14/2021] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE Mediastinal schwannomas are sometimes confused with other neoplasms during initial radiological studies, especially when there is a history of cancer in another area. In these cases, a more accurate analysis using computed tomography (CT) or even magnetic resonance (MRI) is required. Our study aimed to perform a retrospective analysis of the clinical and imaging features for a series of patients with mediastinal schwannomas that were confirmed by histology and immunohistochemistry. RESULTS We found eight patients, five men and three women, with an average age of 51 years for this study. The main signs and symptoms at diagnosis were chest pain, dyspnea, cough, and dysphagia. CT showed that the tumor was located in the posterior compartment of the chest in 7/8 cases. Tumors > 10 cm were more heterogeneous and showed cystic changes. All patients underwent posterolateral thoracotomy, and radiological follow-up showed no evidence of recurrence. Histological analysis was considered the gold standard to confirm diagnosis, along with at least one neurogenic IHC marker. In conclusion, mediastinal schwannomas are benign encapsulated tumors. According to CT, schwannomas > 10 cm show cystic degeneration more frequently. Posterolateral thoracotomy allows complete resection and is considered the surgical approach of choice.
Collapse
Affiliation(s)
- Ramiro Sandoval-Macias
- AFINES Program to Support and Promote Student Research, Medical School, Ciudad Universitaria, UNAM, Mexico City, Mexico
| | - Irving Daniel Ortiz-Sanchez
- AFINES Program to Support and Promote Student Research, Medical School, Ciudad Universitaria, UNAM, Mexico City, Mexico
| | | | - Luis Mora-Hernandez
- Department of Radiology, UMAE Hospital de Oncologia, Centro Medico Nacional Siglo XXI, IMSS, Mexico City, Mexico
| | - Candelaria Cordova-Uscanga
- Department of Pathology, UMAE Hospital de Oncologia, Centro Medico Nacional Siglo XXI, IMSS, Av. Cuauhtemoc No. 330, Col. Doctores, Delegacion Cuauhtemoc, CP 06725, Mexico City, Mexico
| | - Alejandra Mantilla-Morales
- Department of Pathology, UMAE Hospital de Oncologia, Centro Medico Nacional Siglo XXI, IMSS, Av. Cuauhtemoc No. 330, Col. Doctores, Delegacion Cuauhtemoc, CP 06725, Mexico City, Mexico
| | | | - Armando Gamboa-Dominguez
- Department of Pathology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
| | - Fernando Candanedo-Gonzalez
- Department of Pathology, UMAE Hospital de Oncologia, Centro Medico Nacional Siglo XXI, IMSS, Av. Cuauhtemoc No. 330, Col. Doctores, Delegacion Cuauhtemoc, CP 06725, Mexico City, Mexico. .,Department of Pathology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
| |
Collapse
|
5
|
Mantilla-Morales A. Can men's increased susceptibility to COVID-19 be attributed to transmembrane protease serine 2? GAC MED MEX 2020; 156:475. [PMID: 33372939 DOI: 10.24875/gmm.m20000446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- Alejandra Mantilla-Morales
- Oncology Hospital, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
| |
Collapse
|
6
|
Mantilla-Morales A. ¿La mayor susceptibilidad de los hombres a COVID-19 se puede atribuir a la proteasa transmembrana de serina 2? GAC MED MEX 2020. [DOI: 10.24875/gmm.20000504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
7
|
Martínez-Bailón C, Mantilla-Morales A, Méndez-Matías G, Alvarado-Cabrero I, Maldonado-Rodríguez R, Quintero-Becerra J, Arias-Flores R, Piña-Sánchez P. Human papillomavirus genotypes and P16INK4A expression in squamous penile carcinoma in Mexican patients. BMC Infect Dis 2019; 19:1068. [PMID: 31856740 PMCID: PMC6924036 DOI: 10.1186/s12879-019-4696-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2018] [Accepted: 12/09/2019] [Indexed: 01/22/2023] Open
Abstract
Background Approximately 50% of cases of penile carcinoma (PeCa), a rare neoplasm worldwide, are associated with human papillomavirus (HPV). However, the detection of HPV-DNA is not sufficient to consider it the etiological factor in the development of this type of cancer. Currently, the overexpression of P16INK4A is used as a surrogate biomarker of HPV carcinogenesis. Information on PeCa in Mexico is scarce, particularly regarding cases related to HPV and genotype frequency. Objective To evaluate the presence of HPV, its genotypes, and the presence of multiple genotypes, and the expression of P16INK4A, as well as its clinical and histopathological parameters. Methods For HPV-DNA detection and P16INK4A expression, we used the INNO-LiPA® test and immunohistochemistry, respectively. Results Sixty cases of PeCa were evaluated, of which 75% were HPV-non-related histological variants. We found that 58.9% (33/56) of PeCa cases were HPV-DNA positive, while 30.9% of the cases evaluated (17/55) were positive for P16INK4A. HPV16 was the main genotype in 42.9% of the cases, followed by HPV52 in 7.1% and HPV18 in 5.4%. Within the HPV-positive cases, 27.3% had multiple genotypes. All HPV-positive patients under the age of 45 years were positive only for HPV16. Conclusions HPV16 was the most commonly detected genotype in PeCa. HPV 31, 35 and 39 were infrequent; however, they were related to a single infection and P16INK4A overexpression; thus, they seem to be relevant in PeCa carcinogenesis. Our results suggest that P16INK4A overexpression could be useful for the classification of HPV-related PeCa. The role of multiple HPV genotypes in the development and prognosis of PeCa is still not completely understood. Thus, it is necessary to define criteria to establish reliable ways to classify HPV-related PeCa that could lead to optimal therapeutic approaches.
Collapse
Affiliation(s)
- Cecilia Martínez-Bailón
- Molecular Oncology Laboratory, Oncology Research Unit, Instituto Mexicano del Seguro Social, CMN S XXI IMSS, Mexico City, Mexico
| | - Alejandra Mantilla-Morales
- Department of Pathology, UMAE Oncology Hospital, Instituto Mexicano del Seguro Social, CMN S XXI IMSS, Mexico City, Mexico
| | - Galo Méndez-Matías
- Molecular Oncology Laboratory, Oncology Research Unit, Instituto Mexicano del Seguro Social, CMN S XXI IMSS, Mexico City, Mexico
| | - Isabel Alvarado-Cabrero
- Department of Pathology, UMAE Oncology Hospital, Instituto Mexicano del Seguro Social, CMN S XXI IMSS, Mexico City, Mexico
| | - Rogelio Maldonado-Rodríguez
- Department of Biochemistry, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico
| | - Joel Quintero-Becerra
- Department of Urology, UMAE Oncology Hospital, Instituto Mexicano del Seguro Social, CMN S XXI, Mexico City, Mexico
| | - Rafael Arias-Flores
- Department of Epidemiology, UMAE Pediatrics Hospital, Instituto Mexicano del Seguro Social, CMN S XXI, Mexico City, Mexico
| | - Patricia Piña-Sánchez
- Molecular Oncology Laboratory, Oncology Research Unit, Instituto Mexicano del Seguro Social, CMN S XXI IMSS, Mexico City, Mexico.
| |
Collapse
|
8
|
López-Romero R, Rodríguez-Esquivel M, Romero-Morelos P, García-Avilés JE, Serafín-Castillo A, Huerta-Padilla VM, Guerra-Araiza C, Mantilla-Morales A, Monrroy-García A, Aguilar-Urbano MA, Martínez-Castillo MA, Jiménez-Tenorio JA, Salcedo M. The expression of transcription factor BORIS and its association with the estrogen receptor beta (ER-β) in cervical carcinogenesis. Int J Clin Exp Pathol 2019; 12:3208-3221. [PMID: 31934165 PMCID: PMC6949834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Accepted: 07/26/2019] [Indexed: 06/10/2023]
Abstract
BORIS is a transcription factor aberrantly expressed in human cancers that can regulate the expression of estrogen receptors in endometrial cancer and breast cancer. We evaluated the expression of BORIS and the estrogen receptors alpha (ER-α) and beta (ER-β) in ten cell lines derived from cervical cancer using RT-PCR and Western-blot. We also evaluated 54 cervical tissues: normal epithelia, low-grade intraepithelial lesions (LSIL), high-grade intraepithelial lesions (HSIL), and invasive squamous carcinomas (SC) using immunohistochemistry. In the cell lines, BORIS mRNA and protein expressions are associated with ER-β expression but not with ER-α expression. In the normal cervical epithelium, ER-α and ER-β were expressed but the BORIS protein was not detected. In the LSIL samples, BORIS, ER-α and ER-β were expressed; however, in the HSIL samples, only the BORIS and ER-β expressions were detected, but ER-α expression was minimal or null. In the SC, only BORIS and ER-β were detected. In summary, the results show that the expressions of BORIS and ER-β increase while the expression of ER-α decreases according to the severity of the lesions. These results suggest synergistic roles for BORIS and ER-β during cervical cancer progression with a possible regulation of the estrogen receptors by BORIS in the development of cervical cancer; however, more detailed studies are needed to confirm this suggestion and to determine the precise role of BORIS in cervical cancer.
Collapse
Affiliation(s)
- Ricardo López-Romero
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
| | - Miriam Rodríguez-Esquivel
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
- Programa de Doctorado en Nanociencias y Micro y Nanotecnologías, Instituto Politécnico NacionalCDMX México, Mexico
| | - Pablo Romero-Morelos
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
- Laboratorio Multidisciplinario de Investigación, Escuela Militar de Graduados de SanidadSEDENA, 11200 Ciudad de México, Mexico
| | - Jesús Enrique García-Avilés
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
| | - Adán Serafín-Castillo
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
| | - Víctor Mauricio Huerta-Padilla
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
- Programa de Doctorado en Biomedicina y Biotecnología Molecular, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico NacionalCDMX México, Mexico
| | - Christian Guerra-Araiza
- Unidad de Investigación Médica en Farmacología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCDMX, Mexico
| | - Alejandra Mantilla-Morales
- Departamento de Patología, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCDMX, Mexico
| | - Alberto Monrroy-García
- Laboratorio de Inmunología y Cáncer, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCDMX, Mexico
| | - Marco Antonio Aguilar-Urbano
- Departamento de Patología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCDMX, Mexico
| | - Mariana Andrea Martínez-Castillo
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
| | - Julián Antonio Jiménez-Tenorio
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
- Programa de Doctorado en Biomedicina y Biotecnología Molecular, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico NacionalCDMX México, Mexico
| | - Mauricio Salcedo
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialCiudad de México, Mexico
| |
Collapse
|
9
|
Salcedo M, Pina-Sanchez P, Vallejo-Ruiz V, Monroy-Garcia A, Aguilar-Lemarroy A, Cortes-Gutierrez EI, Santos-Lopez G, Montoya-Fuentes H, Grijalva R, Madrid-Marina V, Apresa-Garcia T, Hernandez DM, Jave-Suarez LF, Romero P, Poot A, Salgado E, Ramos-Gonzalez P, Gonzalez-Hernandez R, Canton JC, Jimenez-Aranda L, Parra-Melquiadez M, Paniagua L, Mendoza M, Arreola H, Villegas V, Torres-Poveda K, Bahena-Roman M, Gonzalez-Yebra B, Taniguchi K, Rodea C, Mantilla-Morales A, Mora-Garcia ML, Velazquez-Velazquez CK, Cordova-Uscanga C, Peralta R, Lopez-Romero R, Marrero D, Bandala C, Reyes-Leyva J, Furuya ME, Almeida E, Galvan ME, Grijalva I. Human papillomavirus genotypes among females in Mexico: a study from the Mexican institute for social security. Asian Pac J Cancer Prev 2015; 15:10061-6. [PMID: 25556426 DOI: 10.7314/apjcp.2014.15.23.10061] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The aetiological relationship between human papillomavirus (HPV) infection and cervical cancer (CC) is widely accepted. Our goal was to determine the prevalence of HPV types in Mexican women attending at the Mexican Institute for Social Security from different areas of Mexico. MATERIALS AND METHODS DNAs from 2,956 cervical samples were subjected to HPV genotyping: 1,020 samples with normal cytology, 931 with low-grade squamous intraepithelial lesions (LGSIL), 481 with high grade HGSIL and 524 CC. RESULTS Overall HPV prevalence was 67.1%. A total of 40 HPV types were found; HPV16 was detected in 39.4% of the HPV-positive samples followed by HPV18 at 7.5%, HPV31 at 7.1%, HPV59 at 4.9%, and HPV58 at 3.2%. HPV16 presented the highest prevalence both in women with altered or normal cytology and HPV 18 presented a minor prevalence as reported worldwide. The prevalence ratio (PR) was calculated for the HPV types. The analysis of PR showed that HPV16 presents the highest association with CC, HPV 31, -33, -45, -52 and -58 also demonstrating a high association. CONCLUSIONS The most prevalent HPV types in cervical cancer samples were -16, -18, -31, but it is important to note that we obtained a minor prevalence of HPV18 as reported worldwide, and that HPV58 and -52 also were genotypes with an important prevalence in CC samples. Determination of HPV genotypes is very important in order to evaluate the impact of vaccine introduction and future cervical cancer prevention strategies.
Collapse
Affiliation(s)
- Mauricio Salcedo
- Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security; IMSS), Mexico E-mail :
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
García-Sánchez M, Romero-Durán E, Mantilla-Morales A, Gallegos-Hernández JF. [Histopathological evaluation of the subtotal laryngectomy specimen]. CIR CIR 2015; 83:537-42. [PMID: 26159367 DOI: 10.1016/j.circir.2015.05.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2014] [Accepted: 10/07/2014] [Indexed: 11/18/2022]
Abstract
INTRODUCTION The goal of conservative surgical treatment of laryngeal cancer is to obtain oncological control with preservation of laryngeal function. The concept of laryngeal function preservation should be understood as the preservation of the patient's ability to breathe normally with neither tracheostomy nor aspiration, and maintaining intelligible speech. This can be achieved by a balance between two fundamental aspects, proper patient selection (based on tumour extension and preoperative laryngeal function), and an adequate histopathological analysis of the surgical specimen. Supracricoid subtotal laryngectomy is the voice conservative surgical technique that offers the best possibility of control in patients with locally advanced laryngeal cancer. The proper histopathological analysis allows staging and selecting patients for adjuvant therapy, avoiding unnecessary ones as well as designing monitoring and surveillance programs based on risk factors. OBJECTIVE To highlight key points in the histopathological evaluation of the surgical specimen of a subtotal laryngectomy. CONCLUSION The proper communication between the surgeon and pathologist, offering complete information on preoperative clinical evaluation and the knowledge of the key points in the evaluation of the surgical specimen (sites of tumour leakage and surgical resection margins) are fundamental parameters to achieve a proper histopathological evaluation of the surgical specimen.
Collapse
Affiliation(s)
- Manuel García-Sánchez
- Departamento de Tumores de Cabeza y Cuello, Hospital de Oncología, Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social, México D.F., México
| | - Elizabeth Romero-Durán
- Departamento de Patología, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México D.F., México
| | - Alejandra Mantilla-Morales
- Departamento de Patología, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México D.F., México
| | - José Francisco Gallegos-Hernández
- Departamento de Patología, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México D.F., México.
| |
Collapse
|
11
|
García-Sánchez M, Romero-Durán E, Mantilla-Morales A, Gallegos-Hernández JF. [Subtotal-supracrioid laryngectomy (SCSL): the importance of the histopathological analysis]. GAC MED MEX 2015; 151:105-109. [PMID: 25739490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023] Open
Abstract
The purpose of conservative surgical treatment of laryngeal cancer is to obtain cancer control with preservation of laryngeal function, and in turn, the preservation of laryngeal function should be understood as the preservation of the patient's ability to ventilate in the normal way without tracheostomy and without aspiration and maintaining intelligible speech. This objective is achieved by maintaining a balance between two fundamental aspects: proper patient selection (based on tumor extension and preoperative laryngeal function) and an adequate histopathological analysis of the surgical specimen. Supracricoid subtotal laryngectomy (SCSL) is the voice conservative surgical technique which offers the best possibility of control in patients with locally advanced laryngeal cancer, and the proper histopathological analysis allows staging and selecting patients eligible for adjuvant therapy, avoiding unnecessary therapies, and allows design of a monitoring and surveillance program based on risk factors. The aim of this manuscript is to highlight key points in the histopathological evaluation of the surgical specimen of SCSL. The proper communication between the surgeon and pathologist, offering complete information on preoperative clinical evaluation and the knowledge of the key points in the evaluation of the surgical specimen (sites of tumor leakage and surgical resection margins) are fundamental parameters to achieve a proper histopathologic evaluation of the surgical specimen.
Collapse
Affiliation(s)
- Manuel García-Sánchez
- Departamento de Tumores de Cabeza y Cuello, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México, D.F
| | - Elizabeth Romero-Durán
- Departamento de Patología, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México, D.F
| | - Alejandra Mantilla-Morales
- Departamento de Patología, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México, D.F
| | - José Francisco Gallegos-Hernández
- Departamento de Patología, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México, D.F
| |
Collapse
|
12
|
Villegas-Ruíz V, Salcedo M, Zentella-Dehesa A, de Oca EVM, Román-Basaure E, Mantilla-Morales A, Dávila-Borja VM, Juárez-Méndez S. A case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptor. Int J Clin Exp Pathol 2014; 7:2256-2264. [PMID: 24966934 PMCID: PMC4069874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Accepted: 04/08/2014] [Indexed: 06/03/2023]
Abstract
Cervical cancer is the second malignancy in Mexico, little is known about the prognostic factors associated with this disease. Several cellular components are important in their transformation and progression. Alternative mRNA splice is an important mechanism for generating protein diversity, nevertheless, in cancer unknown mRNA diversity is expressed. Hyaluronan-mediated motility receptor (HMMR, RHAMM, CD168) is a family member of proteins, hyaluronan acid dependent, and has been associated with different malignant processes such as: angiogenesis, cell invasiveness, proliferation, metastasis and poor outcome in some tumors. In the present study we identified expression of HMMR in cervical cancer by means of RT-PCR and sequencing. Our results indicate co-expression of two HMMR variants in all samples, and one case expressed three alternative HMMR splice transcripts. These results showed the heterogeneity of mRNA transcripts of HMMR that could express in cancer and the expression of HMMR could be marker of malignancy in CC.
Collapse
Affiliation(s)
- Vanessa Villegas-Ruíz
- Genomic Oncology Laboratory, Medical Research Unit in Oncologic Diseases, Oncology Hospital, National Medical Center Siglo XXI, IMSSMéxico, D.F., México
| | - Mauricio Salcedo
- Genomic Oncology Laboratory, Medical Research Unit in Oncologic Diseases, Oncology Hospital, National Medical Center Siglo XXI, IMSSMéxico, D.F., México
| | - Alejandro Zentella-Dehesa
- Department of Medical Genomics and Environmental Toxicology, Biomedical Research Institute, UNAMMéxico, D.F., México
- Biochemistry Unit, National Institute of Medical Sciences and Nutrition “Salvador Zubirán”México, D.F., México
| | - Edén V Montes de Oca
- Biochemistry Unit, National Institute of Medical Sciences and Nutrition “Salvador Zubirán”México, D.F., México
| | | | | | - Víctor M Dávila-Borja
- Experimental Oncology Laboratory, Department of Research, National Institute of PediatricsMéxico, D.F., México
| | - Sergio Juárez-Méndez
- Experimental Oncology Laboratory, Department of Research, National Institute of PediatricsMéxico, D.F., México
| |
Collapse
|
13
|
Villegas-Ruiz V, Juárez-Méndez S, Pérez-González OA, Arreola H, Paniagua-García L, Parra-Melquiadez M, Peralta-Rodríguez R, López-Romero R, Monroy-García A, Mantilla-Morales A, Gómez-Gutiérrez G, Román-Bassaure E, Salcedo M. Heterogeneity of microRNAs expression in cervical cancer cells: over-expression of miR-196a. Int J Clin Exp Pathol 2014; 7:1389-1401. [PMID: 24817935 PMCID: PMC4014219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Accepted: 02/15/2014] [Indexed: 06/03/2023]
Abstract
In recent years, the study of microRNAs associated with neoplastic processes has increased. Patterns of microRNA expression in different cell lines and different kinds of tumors have been identified; however, little is known about the alterations in regulatory pathways and genes involved in aberrant set of microRNAs. The identification of these altered microRNAs in several cervical cancer cells and potentially deregulated pathways involved constitute the principal goals of the present study. In the present work, the expression profiles of cellular microRNAs in Cervical Cancer tissues and cell lines were explored using microRNA microarray, Affymetrix. The most over-expressed was miR-196a, which was evaluated by real time PCR, and HOXC8 protein as potential target by immunohistochemistry assay. One hundred and twenty three human microRNAs differentially expressed in the cell tumor, 64 (52%) over-expressed and 59 (48%) under-expressed were observed. Among the microRNAs over-expressed, we focused on miR-196a; at present this microRNA is poorly studied in CC. The expression of this microRNA was evaluated by qRT-PCR, and HOXC8 by immunohistochemistry assay. There is not a specific microRNA expression profile in the CC cells, neither a microRNA related to HPV presence. Furthermore, the miR-196a was over-expressed, while an absence of HOXC8 expression was observed. We suggest that miR-196a could be played as oncomiR in CC.
Collapse
Affiliation(s)
- Vanessa Villegas-Ruiz
- Laboratorio de Oncología Genómica, UIMEO, Hospital de OncologíaCMN-SXXI, IMSS, Mexico
| | - Sergio Juárez-Méndez
- Laboratorio de Oncología Experimental, Instituto Nacional de PediatríaSS, México
| | | | - Hugo Arreola
- Laboratorio de Oncología Genómica, UIMEO, Hospital de OncologíaCMN-SXXI, IMSS, Mexico
| | | | | | | | - Ricardo López-Romero
- Laboratorio de Oncología Genómica, UIMEO, Hospital de OncologíaCMN-SXXI, IMSS, Mexico
| | - Alberto Monroy-García
- Laboratorio de Inmunología y Cáncer, UIMEO, Hospital de OncologíaCMN-SXXI, IMSS, Mexico
| | | | | | | | - Mauricio Salcedo
- Laboratorio de Oncología Genómica, UIMEO, Hospital de OncologíaCMN-SXXI, IMSS, Mexico
| |
Collapse
|
14
|
Pérez-Martínez IJ, Mantilla-Morales A, Cruz-Esquivel I, Gallegos-Hernández JF. [Adnexal neoplasms in the context of skin cancer: trichilemmal carcinoma. Apropos of a case]. CIR CIR 2013; 81:436-440. [PMID: 25125062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND The trichilemmal carcinoma is a rare malignant neoplasm, whose origin lies in the annexes of the skin, because of its low prevalence often confused with other dermal tumors, the differential diagnosis is not easy and is usually made by exclusion; in theory, its behavior is slow with little tendency to send both regional lymph node metastasis and systemic. Due to the limited number of cases there is no consensus on the prognosis, although it is generally considered good. The aim of this report is to show a case that, contrary to previous reports, the clinical presentation is aggressive with large soft tissue tumor infiltration around the site of origin in a patient without risk factors for skin cancer. CLINICAL CASE Male patient, 65 years old with cytologic diagnosis of carcinoma in a preprarotideal facial tumor, characteristics at diagnosis were infiltration of the facial skin, ear, and parotid gland. Complete block resection was performed, radical parotiroidectomy and radical neck dissection; the soft tissue defect was covered with a pediculated flap. The evolution was satisfactory it follow-up short though. We evaluated the experience in the literature regarding the prognosis and treatment of these patients. CONCLUSION Trichilemmal carcinoma can be fully invasive behavior prognosis is difficult to know and probably depends on the clinical stage at diagnosis.
Collapse
Affiliation(s)
- Ignacio Jaime Pérez-Martínez
- Departamento de Tumores de Cabeza y Cuello, Hospital de Oncología, CMN Siglo XXI. Instituto Mexicano del Seguro Social, Mexico DF, Mexico
| | - Alejandra Mantilla-Morales
- Departamento de Patología, Hospital de Oncología, CMN Siglo XXI. Instituto Mexicano del Seguro Social, Mexico DF, Mexico
| | - Iván Cruz-Esquivel
- Departamento de Tumores de Cabeza y Cuello, Hospital de Oncología, CMN Siglo XXI. Instituto Mexicano del Seguro Social, Mexico DF, Mexico
| | - José Francisco Gallegos-Hernández
- Departamento de Tumores de Cabeza y Cuello, Hospital de Oncología, CMN Siglo XXI. Instituto Mexicano del Seguro Social, Mexico DF, Mexico.
| |
Collapse
|
15
|
López-Romero R, Garrido-Guerrero E, Rangel-López A, Manuel-Apolinar L, Piña-Sánchez P, Lazos-Ochoa M, Mantilla-Morales A, Bandala C, Salcedo M. The cervical malignant cells display a down regulation of ER-α but retain the ER-β expression. Int J Clin Exp Pathol 2013; 6:1594-1602. [PMID: 23923078 PMCID: PMC3726975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 06/04/2013] [Accepted: 06/19/2013] [Indexed: 06/02/2023]
Abstract
The human cervix is a tissue target of sex steroid hormones as estradiol (E2) which exerts its action through of the estrogen receptors alpha and beta (ER-α and ER-β). In this study we investigated the expression of ER-α and ER-β in human invasive cervical carcinomas using immunohistochemistry and RT-PCR analyses and compared with that observed in the corresponding normal tissue. The results show nuclear expression of ER-α mainly in the first third of normal cervical epithelium, however, decreased or absent expression were present in invasive cervical carcinoma, indicating that expression of ER-α is lost in cervical cancer. Nevertheless, by RT-PCR we were able to demonstrate mRNA expression of ER-α in invasive cervical tissues. These results suggest that loss of ER-α could be due to a mechanism of post-transcriptional and/or post-translational regulation of its gene during the progression to invasive carcinoma. On the other hand, ER-β was expressed in normal cervix with an expression pattern similar to ER-α. In addition to its nuclear localization, cytoplasmic immunoreaction of ER-β was present in the epithelium of invasive cervical carcinomas, suggesting an association between cytoplasmic ER-β expression and invasive phenotype in the cervical tumors. In summary, the results show that the cervical malignant cells tend to loss the ER-α but maintain the ER-β actively expressed. Loss of expression of ER-α in neoplastic tissue suggests that the estrogenic effects could be conducted through the ER-β in human neoplastic cervical tissue. More detailed studies are needed to confirm this suggestion and to determine the role of ER-β in cervical cancer.
Collapse
Affiliation(s)
- Ricardo López-Romero
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialMéxico D.F.
| | | | - Angélica Rangel-López
- Unidad de Investigación Médica en Enfermedades Nefrológicas, Hospital de Especialidades, Centro Médico Nacional SXXI, Instituto Mexicano del Seguro SocialMexico D.F.
| | - Leticia Manuel-Apolinar
- Unidad de Investigación Médica en Enfermedades Endócrinas, Hospital de Especialidades, Centro Médico Nacional SXXI, Instituto Mexicano del Seguro SocialMexico D.F.
| | - Patricia Piña-Sánchez
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialMéxico D.F.
| | | | - Alejandra Mantilla-Morales
- Departamento de Patología, Hospital de Oncología, Centro Médico Nacional SXXI, Instituto Mexicano del Seguro SocialMexico D.F.
| | - Cindy Bandala
- Unidad de Apoyo a la Investigación, Instituto Nacional de Rehabilitación, Secretaría de SaludMexico D.F.
| | - Mauricio Salcedo
- Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialMéxico D.F.
| |
Collapse
|
16
|
Alvarado-Cabrero I, de Anda-González J, Hernández-Hernández B, Mantilla-Morales A, Valencia-Cedillo R, Medrano-Guzmán R. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital]. Rev Gastroenterol Mex 2012; 77:174-80. [PMID: 23142406 DOI: 10.1016/j.rgmx.2012.08.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 05/11/2012] [Revised: 07/24/2012] [Accepted: 08/08/2012] [Indexed: 10/27/2022]
Abstract
BACKGROUND Neuroendocrine tumors (NETs) present all along the length of the gastrointestinal (GI) tract, from the esophagus to the anus, and they also present in the pancreas. AIMS To classify NETs according to the WHO 2010 criteria and to evaluate their anatomic distribution and clinicopathologic characteristics. MATERIAL AND METHODS A search was carried out in the hospital pathology archives of all the cases diagnosed with carcinoid tumor and neuroendocrine carcinoma of the GI tract and pancreas studied over a period of 11 years (1999-2010). The cases were reclassified according to the WHO 2010 criteria. The clinical case records of each patient were reviewed. RESULTS The study group was made up of 127 cases (68 men; 59 women). Age ranged from 24 to 85 years with a median of 52 years. A total of 113 (89.00%) tumors occurred in the GI tract and 14 (11.00%) in the pancreas. Tumor size varied from 0.4cm to 9cm (median: 2.5cm). GI tumor histologic grades were: 54.00% grade 1; 31.00% grade 2; and 15.00% grade 3. Pancreatic tumor histologic grades were: 43.00% grade 1; 36.00% grade 2; and 21.00% grade 3. Ki-67 overexpression was correlated with tumor grade (22.00% grade 3 vs 2.50% grade 1). CONCLUSIONS Histologic grade of the gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is one of the most important prognostic factors. The term carcinoid should be eliminated because it does not reflect the biological behavior of these tumors.
Collapse
Affiliation(s)
- I Alvarado-Cabrero
- Departamento de Patología, Hospital de Oncología Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México D.F., México.
| | | | | | | | | | | |
Collapse
|
17
|
Ordoñez-Escalante KG, Mantilla-Morales A, Gallegos F. [Nasal cavity angiosarcoma: a case report and literature review]. GAC MED MEX 2006; 142:155-8. [PMID: 16711550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/09/2023] Open
Abstract
Sarcomas constitute 5% of all of head and neck neoplasms. Angiosarcomas comprise 2% of all soft tissue tumors, 60% appear in skin and soft tissue, 50% in the head and neck and only 4% are present in the upper aerodigestive tract. We report a case of a 52 year old healthy woman with headache, weeping, foreign body sensation in the left nostril and epixtasis. The TAC identified a tumor in the left nostril that invaded the osseous lamina of the skull. The histopathologic diagnosis was angiosarcoma. We carried out a literature review and analysis from 1976 to 2004. Agiosarcomas of the upper aerodigestive tract have a better prognosis and long term survival free of disease than their soft tissue and skin counterparts. Recurrence is strongly correlated with positive resection margins. Complete surgery and radiotherapy are considered the optimal treatment schemes.
Collapse
Affiliation(s)
- Karla Gabriela Ordoñez-Escalante
- Servicio de Anatomía Patológica, Hospital de Oncología Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico D. F., Mexico
| | | | | |
Collapse
|
18
|
Mantilla-Morales A, Gallegos-Hernández JF, Posada-Sibaja A. [Histopathologic study of the frontolateral laryngectomy specimen: topics of clinical interest]. CIR CIR 2005; 73:315-8. [PMID: 16283965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Frontolateral laryngectomy is a surgical procedure that allows removal of a vocal cord, anterior commissure, one third of the healthy vocal cord and the thyroid cartilage keel. It is indicated in patients with T1a and T1b glottic-located carcinomas with adverse prognosis factors and selected T2 cases. The success relies on appropriate tumor excision. In order to make an assessment, we need to know the critical topics of clinic interest in the histopathologic study of the specimen. The objective is to analyze which are the significant factors to histologically assess in frontolateral laryngectomy and to report the histological study technique conducted at the Oncology Hospital of the National Medical Center of the Mexican Social Security Institute. According to the critical sites in the surgical technique and significant for local tumor recurrence, we report the histological study technique followed for the frontolateral laryngectomy specimens. The factors to assess in the frontolateral laryngectomy specimen are the anterior third part of the healthy cord, the paraglottic space and the crico-vocal ligament. The pathologic study technique reported herein allows us to satisfactorily assess these risk factors. Macroscopic tumor excision is not sufficient, and a satisfactory histological analysis is required that will allow us to assess the critical sites where there may be residual tumor. These may translate into a higher possibility of tumor recurrence for the patient. Communication between pathologists and surgeons is essential to achieve success in this procedure.
Collapse
|
19
|
Abstract
Micropapillary carcinoma (MPC) of the bladder is a rare and aggressive variant of bladder carcinoma. The goals of this study are to investigate whether this variant of bladder carcinoma represents a more aggressive disease than conventional urothelial carcinoma (CUC) and to determine the incidence of MPC in our country. A total of 630 urothelial carcinomas diagnosed from 1997 to 2003 at the Department of Pathology, Oncology Hospital, in Mexico City were analyzed to identify MPC. Thirty-eight patients were found to have this diagnosis and along with a group of 76 patients diagnosed with CUC serve as the basis for this study. In 37 patients with MPC, the lesions were located in the bladder, and in 1 patient in the ureter. The mean patients' age at diagnosis was 68 years, and the male-female ratio was 37:1. The initial stage at presentation was high in most of the patients: Three patients had stage T1, 8 had stage T2, 18 had stage T3, and 9 had stage T4. The disease-specific survival rate for patients with MPC at 3.1 years was 39.5% (95% confidence interval [CI], 2.7%-3.4%) whereas for patient with CUC was 55.3% (95% CI, 3.9%-4.4%). Patients with a micropapillary component of more than 50% had a relative mortality risk of 2.4 (1.3-4.2), whereas patients with less than 50% of MPC did not have a significantly increased mortality risk (RR, 1.8; 0.5-6.0). In summary, in this study, MPC was far more aggressive clinically than CUC. In Mexico, the incidence of 6% of MPC in relation to CUC and the male-female ratio of 37.1 for MPC are much higher than reported in the literature.
Collapse
Affiliation(s)
- Isabel Alvarado-Cabrero
- Department of Pathology, Mexican Oncology Hospital, National Medical Center, Mexico City 06700, Mexico.
| | | | | | | |
Collapse
|
20
|
Gallegos-Hernandez F, Flores-Diaz R, Arias-Ceballos H, Resendiz-Colosia J, Mantilla-Morales A, Chavez-Garcia M, Hernandez-Sanjuan M, Minauro-Munoz G. Lymphatic mapping and sentinel node biopsy in oral cavity cancer. Ann Surg Oncol 2004. [DOI: 10.1007/bf02524188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
García-Fernández R, Hernández-Hernández DM, Iwasaki-Otake L, Mantilla-Morales A, Ortiz-Rodríguez L, Pichardo-Romero P, Lira-Puerto V. [Scintigraphy with 99mTc-MIBI for assessment of tumor response to preoperative chemotherapy in patients with osteosarcoma]. Rev Invest Clin 2001; 53:324-9. [PMID: 11599479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
In osteogenic sarcoma an increase in patient survival has been observed due to improvement of diagnostic and treatment methods. The objective of the investigation was to determine the usefulness of scintigraphy with 99mTc-MIBI in comparison to clinical revaluation, in order to assess tumor response (sarcoma) to chemotherapy previous to surgery. Patients with histopathological osteogenic sarcoma that received chemotherapy were included, clinical and scintigraphy response was assessed previous to the surgery. The gold standard for comparison was the degree necrosis histopathological analysis of the surgical specimen with measurement. Twelve patients met the inclusion criteria. A was observed a higher correlation between the 99mTc-MIBI and the histopathology. vs. clinical evaluation (0.89 vs. 0.59 respectively). Likewise the sensitivity (Se) and specificity (Sp) were superior (Se and Sp = 100% vs. Se 66.6% and Sp 75%) when therapeutically responses good and null were compared. We may conclude that scintigraphy with 99mTc-MIBI used to asses the response to presurgery chemotherapy in patients with osteogenic sarcoma, together with the clinical assessment, help the physician to make therapeutically decisions with more objectivity and certainly.
Collapse
Affiliation(s)
- R García-Fernández
- Departamento de Medicina Nuclear, Hospital de Oncología CMN Siglo XXI, IMSS Av. Cuauhtémoc 330, Col. Doctores 06720, México, D.F
| | | | | | | | | | | | | |
Collapse
|
22
|
Carranza-Lira S, García-Luna A, Rojas-Herrera E, Mantilla-Morales A. [Cervical pregnancy. Report of a case. Diagnostic and therapeutic considerations]. Ginecol Obstet Mex 1996; 64:297-9. [PMID: 8756189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A patient with cervical pregnancy is reported, in spite of the important bleeding a radical management was not required. Clinical, ultrasonographical and histopathological criteria which are needed for diagnosis are reviewed. Also some management alternatives are discussed.
Collapse
Affiliation(s)
- S Carranza-Lira
- Unidad de Ginecología y Obstetricia, Hospital Médica Sur, México, D.F
| | | | | | | |
Collapse
|
23
|
Arista-Nasr J, González-Romo MA, Mantilla-Morales A, Lazos-Ochoa M, Ortiz-Hidalgo C. Immunoproliferative small intestinal disease in Mexico. Report of four cases and review of the literature. J Clin Gastroenterol 1994; 18:67-71. [PMID: 8113590 DOI: 10.1097/00004836-199401000-00016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The clinicopathologic findings in eight Mexican patients with immunoproliferative small intestinal disease (IPSID) are analyzed. Four of these cases have been previously reported and the remainder were found in a retrospective review of 42 lymphoproliferative disorders of the small bowel (9.5% of the cases at our institution). There were six male and two female patients with an average age of 30 years. Laparotomy with intestinal resection was performed in seven cases. Malignant lymphoma was documented in five and the early phase of IPSID in two patients. The remaining case was diagnosed by means of several endoscopic biopsies. It is concluded that although IPSID seems to be a rare disease in the mestizo population of our country, it may not be exceptional and its diagnosis has probably been overlooked.
Collapse
Affiliation(s)
- J Arista-Nasr
- Department of Pathology, Instituto Nacional de la Nutricion, Salvador Zubiran, Mexico City, Mexico
| | | | | | | | | |
Collapse
|